IL325508A - Levodopa derivatives with fatty acids, preparations containing them, and their uses for the treatment of Parkinson's disease - Google Patents

Levodopa derivatives with fatty acids, preparations containing them, and their uses for the treatment of Parkinson's disease

Info

Publication number
IL325508A
IL325508A IL325508A IL32550825A IL325508A IL 325508 A IL325508 A IL 325508A IL 325508 A IL325508 A IL 325508A IL 32550825 A IL32550825 A IL 32550825A IL 325508 A IL325508 A IL 325508A
Authority
IL
Israel
Prior art keywords
levodopa
parkinson
formulations
disease
treatment
Prior art date
Application number
IL325508A
Other languages
English (en)
Hebrew (he)
Inventor
Deven Patel
Manoj K Mishra
H Rajan Sharma
Gari Leema Reddy Peddareddy
Original Assignee
Dynamic Biologics Inc
Deven Patel
Manoj K Mishra
H Rajan Sharma
Gari Leema Reddy Peddareddy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynamic Biologics Inc, Deven Patel, Manoj K Mishra, H Rajan Sharma, Gari Leema Reddy Peddareddy filed Critical Dynamic Biologics Inc
Publication of IL325508A publication Critical patent/IL325508A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL325508A 2023-07-05 2025-12-21 Levodopa derivatives with fatty acids, preparations containing them, and their uses for the treatment of Parkinson's disease IL325508A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18/218,372 US12036199B1 (en) 2023-07-05 2023-07-05 Levodopa fatty acid derivatives, formulations thereof, and their uses for the treatment of Parkinson's disease
PCT/US2023/028404 WO2025010073A1 (en) 2023-07-05 2023-07-21 Levodopa fatty acid derivatives, formulations thereof, and their uses for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
IL325508A true IL325508A (en) 2026-02-01

Family

ID=91759631

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325508A IL325508A (en) 2023-07-05 2025-12-21 Levodopa derivatives with fatty acids, preparations containing them, and their uses for the treatment of Parkinson's disease

Country Status (9)

Country Link
US (2) US12036199B1 (OSRAM)
EP (1) EP4595956A1 (OSRAM)
JP (1) JP7617334B1 (OSRAM)
KR (1) KR102846332B1 (OSRAM)
CN (1) CN119264002B (OSRAM)
AU (1) AU2024204581B2 (OSRAM)
CA (1) CA3244296C (OSRAM)
IL (1) IL325508A (OSRAM)
WO (1) WO2025010073A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120119464B (zh) * 2025-04-18 2025-12-05 浙江理工大学 一种自清洁型亲水聚四氟乙烯纤维膜的制备方法及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH562199A5 (OSRAM) 1970-10-30 1975-05-30 Hoffmann La Roche
AT324316B (de) * 1973-06-27 1975-08-25 Lannacher Heilmittel Verfahren zur herstellung von neuen racemischen oder optisch aktiven phenylalaninestern
EP1596808A4 (en) * 2003-02-07 2007-04-04 Yissum Res Dev Co L-DOPA AMID DERIVATIVES AND THEIR USE
GB0715712D0 (en) * 2007-08-11 2007-09-19 Proximagen Ltd Amino acid derivatives
US8207369B2 (en) * 2008-02-11 2012-06-26 Ramot At Tel-Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
BR112015022896B1 (pt) * 2013-03-15 2022-08-23 Chongxi Yu Composto de fármacos de alta penetração, composição farmacêutica e seus usos para o tratamento de doenças de parkinson
WO2020166473A1 (ja) * 2019-02-12 2020-08-20 国立大学法人筑波大学 レボドパ誘導体及びその使用
JP7656340B2 (ja) * 2019-06-28 2025-04-03 ダイナミック バイオロジクス インコーポレイテッド レボドパポリマーコンジュゲート、その製剤、およびパーキンソン病の治療のためのそれらの使用

Also Published As

Publication number Publication date
AU2024204581B2 (en) 2025-07-31
EP4595956A1 (en) 2025-08-06
JP7617334B1 (ja) 2025-01-17
US12036199B1 (en) 2024-07-16
CA3244296C (en) 2026-04-28
CA3244296A1 (OSRAM) 2026-04-24
US20250114319A1 (en) 2025-04-10
NZ812405A (en) 2025-07-25
AU2024204581A1 (en) 2025-01-23
CN119264002B (zh) 2025-10-17
KR20250008693A (ko) 2025-01-15
CN119264002A (zh) 2025-01-07
WO2025010073A1 (en) 2025-01-09
KR102846332B1 (ko) 2025-08-18
JP2025013734A (ja) 2025-01-27

Similar Documents

Publication Publication Date Title
NZ591326A (en) An extended release pharmaceutical composition of entacapone or salts thereof
WO2007067495A3 (en) Levodopa prodrug mesylate, compositions thereof, and uses thereof
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
WO2007119177A3 (en) Modified release formulations and methods of treating inflammatory bowel disease
IL158589A (en) Carboxylic acid substituted oxazole derivatives, process for their manufacture, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment and prophylaxis of diseases which are modulated by ppar-alpha and -gamma activators
MXPA04005444A (es) Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
SV2005002085A (es) "bioconversión estereoselectiva de dinitrilos alifáticos en ácidos cianocarboxilicos" ref. pc26182a
WO2011047868A3 (en) Peptides used in the treatment and/or care of the skin, mucous membranes and/or hair and its use in cosmetic or pharmaceutical compositions
EP3852760A4 (en) MATERIAL OF COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF ANALOGS DERIVED AT POSITIONS 9 AND 7 ON THE FL118 PLATFORM FOR THE TREATMENT OF A HUMAN DISEASE
IL282562A (en) Composition and use for the treatment of parkinson's disease and related disorders
WO2008071790A3 (en) Novel compositions and uses thereof
MX2007012794A (es) Composiciones para el tratamiento de trastornos del tejido conectivo de la piel.
MX2025009125A (es) Fito-composiciones
TW200706182A (en) Combination immediate release controlled release levodopa and carbidopa dosage forms
EP4470611A3 (en) Levodopa and carbidopa intestinal gel and methods of use
EP3989939A4 (en) POLYMER CONJUGATE OF LEVODOPA, CORRESPONDING FORMULATIONS, AND THEIR USES FOR THE TREATMENT OF PARKINSON'S DISEASE
MY142431A (en) Oxadiazolones, processes for their preparation and their use as pharmaceuticals
EP4304457A4 (en) TREATMENT OF PARKINSON'S DISEASE
UA90893C2 (ru) Пероральная дозированная форма производных гемцитабина
BRPI0509468A (pt) 1,3,4-oxadiazol-2-onas como modulares de ppar delta e usos das mesmas
EP4087654A4 (en) TREATMENT OF ALZHEIMER'S DISEASE
IL285160A (en) Low dose pridopidine for parkinson’s disease and other diseases associated with parkinsonism
KR102467285B9 (ko) 우황청심환을 포함하는 파킨슨 질환 예방 또는 치료용 약학 조성물
IL315725A (en) Methods and preparations for the treatment of Parkinson's disease
HK40120443A (en) Methods and compositions for the treatment of parkinson's disease